Table: Taisho Pharmaceutical HD - 6-MTH group results
Nov 10 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2022 Sep 30, 2021 Mar 31, 2023
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 144.52 130.16 280.50
(+11.0 pct) (-10.8 pct) (+4.6 pct)
Operating 12.21 2.31 16.00
(+427.6 pct) (-85.8 pct) (+48.9 pct)
Recurring 17.34 4.22 20.00
(+310.7 pct) (-77.6 pct) (+8.6 pct)
Net 10.88 2.91 12.00
(+274.0 pct) (-74.3 pct) (-8.6 pct)
EPS 132.68 yen 35.95 yen 146.26 yen
EPS Diluted 132.52 yen 35.90 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10